School of Medicine


Showing 221-230 of 235 Results

  • Avani Gupta

    Avani Gupta

    Director of Strategy and Operations, Center for Digital Health, Medicine - Med/General Internal Medicine

    Current Role at Stanford Director of Strategy and Operations, Center for Digital Health

  • Neel K. Gupta, MD

    Neel K. Gupta, MD

    Clinical Assistant Professor, Medicine - Oncology

    Current Research and Scholarly Interests I have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.

  • Pratyush Gupta

    Pratyush Gupta

    Postdoctoral Research Fellow, Chemical and Systems Biology

    Current Research and Scholarly Interests Diabetes and insulin-resistance affect a staggering 8.3% of world’s population and are a leading cause of death worldwide (World Health Organization). It has a huge impact on global health. Diabetes is the seventh leading cause of death in U.S. and more than 1/3 of U.S. population is resistant to insulin (American Diabetes Association). Insulin-resistance is tightly linked to adipocyte differentiation dysfunction and to defects in adipogenesis. Thus, it becomes necessary to study the molecular and genetic implications of adipogenesis in order to understand mechanisms that can help us to treat insulin-resistance and diabetes. Adipocytes store fat and since accumulation of fat (or obesity) is directly related to development of insulin-resistance, proper control of adipogenesis can link to regulation of accumulation of fat and help us develop strategies to prevent diabetes. That is the goal of this research – to understand how adipocyte differentiation is regulated and use that information to develop therapeutics. The overall goal is find out what feedback loops participate in controlling the terminal differentiation rate of adipocytes as a means to control fat storage and prevent insulin-resistance and diabetes. Through this research, I intend to investigate how post-translational regulation such as proteasomal-degradation, sumoylation and neddylation are involved in mediating the differentiation switch and adipogenesis. This knowledge will be crucial in developing therapeutic strategies to prevent insulin-resistance and diabetes. Diabetes being a leading cause of concern for people, my research will have significant positive consequences on the health of people throughout the world.

  • Rohit Gupta

    Rohit Gupta

    Director, Spectrum Biobank, HIMC Biobank, School of Medicine - General Clinical Research Center

    Current Role at Stanford Director, Biobank | Stanford School of Medicine | Spectrum
    Director, Biobank | Stanford School of Medicine | Human Immune Monitoring Center
    Co-director, HIMC Gateway | Stanford School of Medicine | Human Immune Monitoring Center
    Co-director, Data Coordination and Management Group | Leadership Committee | Accelerating Medicines Partnerships Consortium

  • Irina Gurevich

    Irina Gurevich

    Postdoctoral Research Fellow, Infectious Diseases

    Bio I am a Postdoctoral Fellow in the Department of Medicine. Prior to my arrival at Stanford, I completed my PhD studies in the laboratory of Prof.Guy Shakhar in the Department of Immunology at the Weizmann Institute of Science. While studying at the Weizmann Institute, I contributed to a number of projects working on both in vivo rodent models and on freshly isolated lymphocytes in vitro. My projects involved investigation of immune cell behavior, function and interactions. Over the course of my graduate career, I gained comprehensive knowledge in time-lapse microscopy of living cells and became an expert in intravital two photon imaging of anesthetized mice.
    My educational and occupational path has given me experience in the fields of biotechnology, engineering, analytical chemistry and immunology. These diverse experiences have opened my mind to new complex questions and given me the confidence to take on challenging projects. Looking forward to my time as a Postdoctoral Fellow, I am excited to apply the knowledge I have gained to the pressing problems currently facing the field clinical immunology.